Pages that link to "Q40520942"
Jump to navigation
Jump to search
The following pages link to A DNA vaccine induces SARS coronavirus neutralization and protective immunity in mice (Q40520942):
Displaying 50 items.
- A host type I interferon response is induced by cytosolic sensing of the bacterial second messenger cyclic-di-GMP (Q24642631) (← links)
- Molecular mechanisms of severe acute respiratory syndrome (SARS) (Q24799739) (← links)
- Correcting errors in synthetic DNA through consensus shuffling (Q24805929) (← links)
- Chloroquine is a potent inhibitor of SARS coronavirus infection and spread (Q24815979) (← links)
- A combined nucleocapsid vaccine induces vigorous SARS-CD8+ T-cell immune responses (Q24816925) (← links)
- Plant-produced candidate countermeasures against emerging and reemerging infections and bioterror agents (Q26783107) (← links)
- Human coronaviruses: insights into environmental resistance and its influence on the development of new antiseptic strategies (Q27011643) (← links)
- Current advancements and potential strategies in the development of MERS-CoV vaccines (Q27012578) (← links)
- Dissolving and biodegradable microneedle technologies for transdermal sustained delivery of drug and vaccine (Q27013822) (← links)
- Multivalent HA DNA vaccination protects against highly pathogenic H5N1 avian influenza infection in chickens and mice (Q27301043) (← links)
- Alginic acid-coated chitosan nanoparticles loaded with legumain DNA vaccine: effect against breast cancer in mice (Q27331013) (← links)
- Biodistribution of DNA Plasmid Vaccines against HIV-1, Ebola, Severe Acute Respiratory Syndrome, or West Nile Virus Is Similar, without Integration, despite Differing Plasmid Backbones or Gene Inserts (Q27486035) (← links)
- Structural insights into immune recognition of the severe acute respiratory syndrome coronavirus S protein receptor binding domain (Q27654446) (← links)
- Emerging infectious diseases: a 10-year perspective from the National Institute of Allergy and Infectious Diseases (Q28383084) (← links)
- Severe acute respiratory syndrome coronavirus as an agent of emerging and reemerging infection (Q28383088) (← links)
- Neutralizing antibody response and SARS severity (Q28385241) (← links)
- Effect of mucosal and systemic immunization with virus-like particles of severe acute respiratory syndrome coronavirus in mice (Q28751866) (← links)
- Vaccine efficacy in senescent mice challenged with recombinant SARS-CoV bearing epidemic and zoonotic spike variants (Q28764574) (← links)
- A decade after SARS: strategies for controlling emerging coronaviruses (Q28817689) (← links)
- Global research trends of World Health Organization's top eight emerging pathogens (Q30151375) (← links)
- SARS: future research and vaccine. (Q30344173) (← links)
- Protection against multiple influenza A subtypes by vaccination with highly conserved nucleoprotein. (Q30351034) (← links)
- Obstacles and advances in SARS vaccine development. (Q30351493) (← links)
- Anti-SARS coronavirus agents: a patent review (2008 - present). (Q30352512) (← links)
- Protective immunity to lethal challenge of the 1918 pandemic influenza virus by vaccination. (Q30357455) (← links)
- The pathology and pathogenesis of experimental severe acute respiratory syndrome and influenza in animal models. (Q30359619) (← links)
- Protection from SARS coronavirus conferred by live measles vaccine expressing the spike glycoprotein. (Q30359923) (← links)
- Phase 1 study of pandemic H1 DNA vaccine in healthy adults (Q30373824) (← links)
- Vaccines in a hurry. (Q30377366) (← links)
- A Highly Immunogenic and Protective Middle East Respiratory Syndrome Coronavirus Vaccine Based on a Recombinant Measles Virus Vaccine Platform. (Q30378994) (← links)
- DNA vaccine encoding Middle East respiratory syndrome coronavirus S1 protein induces protective immune responses in mice (Q30400066) (← links)
- Chimeric severe acute respiratory syndrome coronavirus (SARS-CoV) S glycoprotein and influenza matrix 1 efficiently form virus-like particles (VLPs) that protect mice against challenge with SARS-CoV. (Q30404941) (← links)
- B-cell responses in patients who have recovered from severe acute respiratory syndrome target a dominant site in the S2 domain of the surface spike glycoprotein (Q31149856) (← links)
- Immunogenicity and protective efficacy in monkeys of purified inactivated Vero-cell SARS vaccine (Q33230687) (← links)
- Rapid peptide-based screening on the substrate specificity of severe acute respiratory syndrome (SARS) coronavirus 3C-like protease by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (Q33239175) (← links)
- Cynomolgus macaque as an animal model for severe acute respiratory syndrome (Q33239453) (← links)
- Selection of SARS-coronavirus-specific B cell epitopes by phage peptide library screening and evaluation of the immunological effect of epitope-based peptides on mice (Q33261049) (← links)
- A dominant antigenic epitope on SARS-CoV spike protein identified by an avian single-chain variable fragment (scFv)-expressing phage (Q33278644) (← links)
- Chicken single-chain variable fragments against the SARS-CoV spike protein. (Q33291389) (← links)
- The expression and antigenicity of a truncated spike-nucleocapsid fusion protein of severe acute respiratory syndrome-associated coronavirus (Q33387723) (← links)
- Comparative efficacy of hemagglutinin, nucleoprotein, and matrix 2 protein gene-based vaccination against H5N1 influenza in mouse and ferret (Q33547457) (← links)
- Characterization of SARS-CoV-specific memory T cells from recovered individuals 4 years after infection (Q33552505) (← links)
- Neutralizing epitopes of the SARS-CoV S-protein cluster independent of repertoire, antigen structure or mAb technology (Q33688229) (← links)
- H-2 Kd-restricted hepatitis B virus-derived epitope whose specific CD8+ T lymphocytes can produce gamma interferon without cytotoxicity (Q33754985) (← links)
- Aged BALB/c mice as a model for increased severity of severe acute respiratory syndrome in elderly humans (Q33755105) (← links)
- Evasion of antibody neutralization in emerging severe acute respiratory syndrome coronaviruses (Q33756740) (← links)
- Evaluation of human monoclonal antibody 80R for immunoprophylaxis of severe acute respiratory syndrome by an animal study, epitope mapping, and analysis of spike variants (Q33780455) (← links)
- Recombinant modified vaccinia virus Ankara expressing the spike glycoprotein of severe acute respiratory syndrome coronavirus induces protective neutralizing antibodies primarily targeting the receptor binding region. (Q33834543) (← links)
- Enhanced breadth of CD4 T-cell immunity by DNA prime and adenovirus boost immunization to human immunodeficiency virus Env and Gag immunogens (Q33843258) (← links)
- Severe acute respiratory syndrome (SARS) S protein production in plants: development of recombinant vaccine (Q33863306) (← links)